Trexquant Investment LP Sells 13,689 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Trexquant Investment LP trimmed its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 17.1% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 66,249 shares of the company’s stock after selling 13,689 shares during the quarter. Trexquant Investment LP’s holdings in Vaxcyte were worth $5,423,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of PCVX. Norges Bank bought a new stake in shares of Vaxcyte in the fourth quarter worth approximately $90,069,000. Vanguard Group Inc. boosted its holdings in Vaxcyte by 4.6% in the fourth quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company’s stock worth $979,184,000 after purchasing an additional 521,204 shares during the last quarter. Franklin Resources Inc. grew its position in Vaxcyte by 13.2% in the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock worth $315,162,000 after purchasing an additional 324,560 shares during the period. Raymond James Financial Inc. bought a new position in shares of Vaxcyte during the 4th quarter valued at $21,669,000. Finally, Geode Capital Management LLC boosted its stake in shares of Vaxcyte by 10.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company’s stock worth $308,675,000 after buying an additional 259,010 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Performance

Shares of PCVX stock opened at $31.60 on Friday. The stock has a fifty day simple moving average of $74.59 and a two-hundred day simple moving average of $89.85. The firm has a market capitalization of $4.07 billion, a PE ratio of -6.87 and a beta of 1.26. Vaxcyte, Inc. has a 52-week low of $29.57 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Needham & Company LLC reduced their price objective on Vaxcyte from $140.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday. Bank of America lowered their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a research note on Tuesday. Guggenheim restated a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Evercore ISI upgraded shares of Vaxcyte to a “strong-buy” rating in a research report on Monday, March 31st. Finally, The Goldman Sachs Group cut their price objective on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a research report on Tuesday. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $136.50.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total value of $692,080.00. Following the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at approximately $9,472,066.41. The trade was a 6.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now directly owns 7,175 shares of the company’s stock, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,250 shares of company stock valued at $3,170,738. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.